News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Investing.com -- AbbVie Inc. (NYSE: ABBV) reported second-quarter earnings before the open on Friday, missing profit expectations, although revenue beat the consensus estimate. Adjusted earnings per share came in at $3.65, missing analyst estimates of $3.71, while revenue of $16.99 billion exceeded the consensus …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%AbbVie slightly reduced its 2026 profit forecast due to its planned acquisition of Apogee Therapeutics, which is expected to cut full-year earnings by 4 cents per share. Despite this, the company exceeded second-quarter estimates with strong immunology drug sales from Skyrizi and Rinvoq, counteracting …
AbbVie Inc. exceeded Wall Street's second-quarter profit and sales expectations, driven by robust performance in its immunology and neuroscience divisions. The company's top-selling drugs, including the wrinkle-smoothing injection Botox, outperformed forecasts, with Botox sales showing improvement for the third consecutive quarter. Adjusted earnings also …
LSP V Cooperatieve U.A. and LSP V Management B.V. have reported an amended beneficial ownership stake of 4.9% in Pharvaris N.V. (PHVS), based on a Schedule 13G/A filing. This percentage represents 3,424,609 ordinary shares out of 69,666,453 shares outstanding following an underwritten offering in …
DBV Technologies, a biopharmaceutical company, is positioned for a potential revenue-generating commercial model with its Viaskin Peanut immunotherapy patch for pediatric peanut allergy. Analysts project significant revenue growth and a shift to profitability, driven by a stable addressable market and ongoing clinical program expansion. …
This article provides a valuation analysis of Banco Bbva Argentina SA (BBAR), noting its current valuation score of 8.22, which ranks 172 out of 395 in the Banking Services industry. The P/E ratio is currently 20.09, which is 10.72% below its recent high and …
Sharemaestro market context Trend signal active 52 weeks +34.3% · Next-week setup positive 57.2%This article provides a technical analysis of BV Financial Inc (BVFL), detailing its current price momentum score, support and resistance levels, and key technical indicators. It presents a summary of various indicators like MACD, RSI, and Moving Averages, offering insights into potential buy, sell, …
This article provides a risk assessment for BV Financial Inc (BVFL), highlighting its stock score, beta value, and various volatility metrics. BVFL has a risk assessment score of 3.92, ranking 345 out of 395 in the Banking Services industry, with a beta of 0.01 …
This article displays a page dedicated to the financial information of Banco BBVA Argentina SA (BCBA:BBAR.CI) on TradingView, specifically focusing on changes in its working capital. The page provides an overview of financials, documents, news, and other data for the company. While the main …
DBV Technologies has successfully raised $50 million through an At-The-Market (ATM) offering of American Depositary Shares (ADS) on Nasdaq. This funding, achieved by issuing 3.66 million ADS at $13.67 each, will bolster the company's financial standing and support the advanced development of its VIASKIN® …
DBV Technologies announced it has sold approximately $50 million worth of American Depositary Shares (ADSs) through its At-The-Market (ATM) program on Nasdaq. This transaction was conducted between July 1, 2026, and July 31, 2026, utilizing its existing prospectus supplement. The company stated this strategic …
DBV Technologies completed a private placement, selling 3,657,644 ADSs to RA Capital for approximately $50 million gross through its Nasdaq at-the-market program. This transaction, priced at $13.67 per ADS, represents a 0.15% discount to the prior Euronext Paris close and will result in about …
AbbVie Inc. (ABBV) shares declined by 2.24% to $257.41, breaking a two-day winning streak, despite an overall positive trading day for the broader market. Both the S&P 500 Index and the Dow Jones Industrial Average saw gains on Thursday. This report highlights AbbVie's performance …
This amended Schedule 13D/A filing details that the Van Herk reporting persons, holding 10.9% of ProQR Therapeutics N.V., have initiated a petition for a governance investigation and the appointment of an independent non-executive director. The petition was filed on July 27, 2026, with the …
What To Expect From AbbVie's (ABBV) Q2 Earnings Pharmaceutical company AbbVie (NYSE:ABBV) will be announcing earnings results this Friday before market hours. Here's what to look for. AbbVie beat analysts' revenue expectations last quarter, reporting revenues of $15 billion, up 12.4% year on year. …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%Short interest in ProQR Therapeutics (NASDAQ:PRQR) surged by 92.5% in July, reaching 2.31 million shares, representing 2.4% of outstanding shares and 1.8 days to cover. Despite a mixed analyst sentiment, with a consensus "Moderate Buy" rating and an average price target of $7.33, the …
AbbVie's Allergan Aesthetics announced the fourth annual JUVÉDERM® Day will occur on August 19, 2026, coinciding with the 20th anniversary of the brand's first U.S. FDA dermal filler approval. Allē members can access a buy-one-get-one $75 JUVÉDERM® gift card promotion and double Allē points …
Allergan Aesthetics celebrates fourth annual JUVÉDERM®Day with buy-one-get-one (BOGO) gift cards and double points for Allē Members This summer marks the 20th anniversary of the brand's first U.S. Food and Drug Administration (FDA) dermal filler approval Join Allē today to take advantage of limited …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%BV Financial (BVFL) reported an increase in Q2 2026 adjusted net income to 47 cents per share, up from 37 cents in the prior-year quarter, primarily due to higher net interest income driven by lower funding costs. The company's net interest margin improved to …
ProQR Therapeutics (NASDAQ:PRQR) is set to announce its Q2 2026 earnings before market open on Thursday, August 6th, with an earnings call scheduled for August 11th. Analysts project a loss of $0.14 per share on revenue of $4.56 million, following a previous quarter where …
This article provides a valuation analysis of Brightview Holdings Inc (BV), noting its current valuation score of 7.92, ranking 118 out of 159 in its industry. The company's P/E ratio is 439.75, which is 11.49% below its recent high and significantly above its recent …
BV Financial Inc (BVFL) has an institutional shareholding score of 3.00, placing it 250th out of 395 in the Banking Services industry. The institutional shareholding proportion is 39.77%, which is a 42.46% decrease quarter-over-quarter. Bill Nygren | OAKMX is the largest institutional shareholder, holding …
This article provides a risk assessment for ATAI Life Sciences NV (ATAI), ranking it 99 out of 385 in the Biotechnology & Medical Research industry with a score of 4.10. Key metrics include a beta of 1.60, indicating higher volatility than the S&P 500, …
This article provides a detailed financial analysis of New Century Logistics (BVI) Ltd (NCEW), presenting its profitability and balance sheet data. It includes key financial indicators from the FY2025 earnings report, such as revenue, EPS, various assets and liabilities, and profitability ratios. The analysis …
This article provides a risk assessment for Banco Bbva Argentina SA (BBAR), indicating a current risk score of 3.78 and placing it 350th out of 394 in the Banking Services industry. The company's beta of 1.00 suggests it mirrors the S&P 500's volatility, outperforming …
This article provides a revenue breakdown for AbbVie, Inc. CDR (CAD Hedged) under the ticker NEO:ABBV, sourced from TradingView. It highlights that the United States was the primary contributor to AbbVie's revenue, bringing in 65.12 billion CAD last year and 58.95 billion CAD the …
This article provides a revenue breakdown for AbbVie, Inc. Brazilian Depository Receipts (ABBV34) traded on the BMFBOVESPA, highlighting that the United States is the largest contributor to its revenue. The financial data indicates significant revenue in BRL during the last two years.
AbbVie (ABBV) stock appears expensive at first glance with a high price-to-earnings multiple, but a deeper analysis reveals it's cheaper than it seems. When factoring in expected earnings by 2027, the stock's valuation drops significantly due to anticipated growth. This "forward discount" is driven …
Sharemaestro market context Trend signal active 52 weeks +9.6%Aberdeen Group plc and its affiliate abrdn Inc. have disclosed a beneficial ownership of 8,932,507 Ordinary Shares in ProQR Therapeutics N.V., representing 6.33% of the class. Both entities report shared voting and dispositive power over these shares, which abrdn Inc. holds on behalf of …
Eli Lilly (NYSE: LLY) brought in $19.8 billion in revenue in the first quarter of 2026, and most of it can be traced back to the medicines everyone has heard of by now: tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for …
AbbVie (ABBV) has seen strong returns over five years (172%), but its current valuation presents a mixed picture. While a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 43.4% at an intrinsic value of $465 per share, its Price-to-Earnings (P/E) ratio …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%Search by ticker symbol or company name and select a result to open its chart.